Cerecor Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Michael Cola
- Full Time Employees
- 30
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 540 Gaither Rd Ste 400 Rockville MD United States of America 20850
- IPO Date
- Nov 13, 2015
- CIK
- 0001534120
- Website
- cerecor.com
- Similar Companies
- Business
- Cerecor Inc. (NASDAQ: CERC), formerly a biopharmaceutical company focused on the development and commercialization of treatments for rare pediatric and orphan diseases, completed its transition to Avalo Therapeutics Inc. (NASDAQ: AVTX) through a corporate name change in August 2021. Avalo Therapeutics operates as a clinical-stage biotechnology company dedicated to developing IL-1β-based therapies for immune-mediated inflammatory diseases; its lead product candidate, AVTX-009, advances in a Phase 2 clinical trial for hidradenitis suppurativa, with additional exploration into other prevalent inflammatory indications featuring significant unmet needs. The company's prior pipeline under the Cerecor name encompassed clinical-stage assets targeting rare diseases, including CERC-002 (anti-LIGHT monoclonal antibody for severe pediatric-onset Crohn's disease and COVID-19 acute respiratory distress syndrome), CERC-007 (anti-IL-18 monoclonal antibody for Still’s disease and multiple myeloma), CERC-006 (oral mTORC1/2 inhibitor for complex lymphatic malformations), and the CERC-800 series (CERC-801, CERC-802, CERC-803; monosaccharide therapies for congenital disorders of glycosylation, each with Orphan Drug, Fast Track, and Rare Pediatric Disease Designations). Founded in 2011 and headquartered in Rockville, Maryland, Cerecor executed several major strategic changes in recent years, including the 2020 merger with Aevi Genomic Medicine that expanded its pipeline to six clinical-stage assets and appointed new leadership; a $35 million debt financing agreement with Horizon Technology Finance in 2021 to fund clinical development; divestitures of non-core neurological assets and commercial products like Millipred; and the 2021 rebranding to Avalo Therapeutics to streamline focus on immunology programs such as AVTX-002 (anti-LIGHT) and AVTX-007 (anti-IL-18), alongside AVTX-800 series opportunities. These shifts positioned the entity to prioritize high-value biologics in immune-inflammatory diseases across the United States and international markets, supported by prior funding rounds like a $33 million public offering in 2021 and eligibility for Priority Review Vouchers on select assets.
Avalo Therapeutics, Inc. Announces Corporate Name Change from Cerecor Inc.
Cerecor Reports Second Quarter 2021 Financial Results and Provides Business Updates
Cerecor Announces Drawdown of $10 Million Tranche under its Debt Financing Agreement with Horizon Technology Finance
Cerecor's Crohn's Disease Candidate Shows Encouraging Response In Pretreated Patients
Cerecor Licenses Immune Checkpoint Program from Sanford Burnham Prebys Further Expanding Pipeline of Immunology and Immuno-oncology Targets
Top Penny Stocks to Buy Moving in Premarket? Check These 3 Out
Cerecor Shares Gain After FDA Fast Track Review Tag For CERC-002 In Hospitalized COVID-19 Patients
Cerecor's investigational COVID-19 therapy gets Fast Track designation from the FDA
A Small Biotech Stock That Has All The Right Ingredients for a Big 2021 Breakout
Cerecor Inks New Global License Agreement With Kyowa Kirin For CERC-002
Cerecor Reports 2020 Financial Results and Provides Business Updates
Cerecor to Present at Upcoming Investor Conferences
CERC Stock Price Increases Over 10% Pre-Market: Why It Happened
Cerecor Announces Fast Track Designation for CERC-803 for the Treatment of Leukocyte Adhesion Deficiency Type II
Cerecor Announces Proceeds from Option to Purchase Additional Shares of Common Stock Bringing Public Offering Proceeds to $40.7 Million
Cerecor Inc. Announces Closing of $36.4 Million Public Offering of Common Stock and Pre-Funded Warrants
Cerecor Inc. Announces Pricing of $36.4 Million Public Offering of Common Stock and Pre-Funded Warrants
Cerecor Inc. Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Cerecor Announces FDA Acceptance of Investigational New Drug Application for CERC-007 for the Treatment of Still's Disease
Cerecor Announces First Patient Dosed in a Phase 1b Clinical Trial of CERC-007 for the Treatment of Relapsed or Refractory Multiple Myeloma